Ratings H.U. Group Holdings, Inc.

Equities

4544

JP3822000000

Delayed Japan Exchange Other stock markets 08:14:26 2024-04-17 pm EDT			5-day change	1st Jan Change
2,385 ^JPY	-0.21%		-1.14%	-10.47%

Mar. 13	H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	MT
Mar. 13	Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

With regards to fundamentals, the enterprise value to sales ratio is at 0.73 for the current period. Therefore, the company is undervalued.
The company appears to be poorly valued given its net asset value.
This company will be of major interest to investors in search of a high dividend stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company sustains low margins.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
H.U. GROUP HOLDINGS, INC.	-10.47%	887M		A-
SONIC HEALTHCARE LIMITED	-18.92%	8.15B		B+
RADNET, INC.	+37.47%	3.53B		C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-26.35%	3.02B		B-
SYNLAB AG	-7.18%	2.49B		-
DR. LAL PATHLABS LIMITED	-9.71%	2.31B		B-
NEOGENOMICS, INC.	-15.45%	1.77B		C-
FLEURY S.A.	-23.06%	1.45B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.05%	1.26B		C+
ADICON HOLDINGS LIMITED	-11.04%	1.14B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes